Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Nov;57(Suppl):15–17. doi: 10.1136/jnnp.57.suppl.15

In vitro effects of polyvalent immunoglobulin for intravenous use.

I N van Schaik 1, M Vermeulen 1, A Brand 1
PMCID: PMC1016716  PMID: 7964843

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arend W. P., Smith M. F., Jr, Janson R. W., Joslin F. G. IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol. 1991 Sep 1;147(5):1530–1536. [PubMed] [Google Scholar]
  2. Arsura E. Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol. 1989 Nov;53(2 Pt 2):S170–S179. doi: 10.1016/0090-1229(89)90083-4. [DOI] [PubMed] [Google Scholar]
  3. Bartlett W. C., Purchio A., Fell H. P., Noelle R. J. Cognate interactions between helper T cells and B cells. VI. TGF-beta inhibits B cell activation and antigen-specific, physical interactions between Th and B cells. Lymphokine Cytokine Res. 1991 Jun;10(3):177–183. [PubMed] [Google Scholar]
  4. Basta M., Kirshbom P., Frank M. M., Fries L. F. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest. 1989 Dec;84(6):1974–1981. doi: 10.1172/JCI114387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chaudhry V., Corse A. M., Cornblath D. R., Kuncl R. W., Drachman D. B., Freimer M. L., Miller R. G., Griffin J. W. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 1993 Mar;33(3):237–242. doi: 10.1002/ana.410330303. [DOI] [PubMed] [Google Scholar]
  6. Cherin P., Herson S., Wechsler B., Piette J. C., Bletry O., Coutellier A., Ziza J. M., Godeau P. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991 Aug;91(2):162–168. doi: 10.1016/0002-9343(91)90009-m. [DOI] [PubMed] [Google Scholar]
  7. Cherin P., Herson S., Wechsler B., Piette J. C., Bletry O., Coutellier A., Ziza J. M., Godeau P. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991 Aug;91(2):162–168. doi: 10.1016/0002-9343(91)90009-m. [DOI] [PubMed] [Google Scholar]
  8. Clement L. T. Isoforms of the CD45 common leukocyte antigen family: markers for human T-cell differentiation. J Clin Immunol. 1992 Jan;12(1):1–10. doi: 10.1007/BF00918266. [DOI] [PubMed] [Google Scholar]
  9. Cook L., Howard J. F., Jr, Folds J. D. Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis. J Clin Immunol. 1988 Jan;8(1):23–31. doi: 10.1007/BF00915153. [DOI] [PubMed] [Google Scholar]
  10. Cornblath D. R., Chaudhry V., Griffin J. W. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol. 1991 Jul;30(1):104–106. doi: 10.1002/ana.410300119. [DOI] [PubMed] [Google Scholar]
  11. Delfraissy J. F., Tchernia G., Laurian Y., Wallon C., Galanaud P., Dormont J. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol. 1985 Jun;60(2):315–322. doi: 10.1111/j.1365-2141.1985.tb07417.x. [DOI] [PubMed] [Google Scholar]
  12. Dietrich G., Pereira P., Algiman M., Sultan Y., Kazatchkine M. D. A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines and idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). J Autoimmun. 1990 Oct;3(5):547–557. doi: 10.1016/s0896-8411(05)80020-4. [DOI] [PubMed] [Google Scholar]
  13. Engelhard D., Waner J. L., Kapoor N., Good R. A. Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr. 1986 Jan;108(1):77–81. doi: 10.1016/s0022-3476(86)80772-7. [DOI] [PubMed] [Google Scholar]
  14. Fehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. 1982 May 27;306(21):1254–1258. doi: 10.1056/NEJM198205273062102. [DOI] [PubMed] [Google Scholar]
  15. Frank M. M., Basta M., Fries L. F. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S82–S86. doi: 10.1016/0090-1229(92)90045-p. [DOI] [PubMed] [Google Scholar]
  16. Hashimoto F., Sakiyama Y., Matsumoto S. The suppressive effect of gammaglobulin preparations on in vitro pokeweed mitogen-induced immunoglobulin production. Clin Exp Immunol. 1986 Aug;65(2):409–415. [PMC free article] [PubMed] [Google Scholar]
  17. Hodge J. W., Wust C. J., Ichiki A. T., Lozzio C. B. Antibodies to specific cell surface antigens of a human leukemia cell line, K-562, transduce negative growth signals. Ann N Y Acad Sci. 1991;628:165–168. doi: 10.1111/j.1749-6632.1991.tb17236.x. [DOI] [PubMed] [Google Scholar]
  18. Illum N., Taudorf K., Heilmann C., Smith T., Wulff K., Mansa B., Platz P. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics. 1990 May;21(2):87–90. doi: 10.1055/s-2008-1071468. [DOI] [PubMed] [Google Scholar]
  19. Jayne D. R., Davies M. J., Fox C. J., Black C. M., Lockwood C. M. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991 May 11;337(8750):1137–1139. doi: 10.1016/0140-6736(91)92797-6. [DOI] [PubMed] [Google Scholar]
  20. Jungi T. W., Santer M., Lerch P. G., Barandun S. Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study. Vox Sang. 1986;51(1):18–26. doi: 10.1111/j.1423-0410.1986.tb00203.x. [DOI] [PubMed] [Google Scholar]
  21. Kaji R., Shibasaki H., Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology. 1992 Mar;42(3 Pt 1):506–509. doi: 10.1212/wnl.42.3.506. [DOI] [PubMed] [Google Scholar]
  22. Kaveri S. V., Dietrich G., Hurez V., Kazatchkine M. D. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol. 1991 Nov;86(2):192–198. doi: 10.1111/j.1365-2249.1991.tb05794.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kawada K., Terasaki P. I. Evidence for immunosuppression by high-dose gammaglobulin. Exp Hematol. 1987 Feb;15(2):133–136. [PubMed] [Google Scholar]
  24. Kondo N., Ozawa T., Mushiake K., Motoyoshi F., Kameyama T., Kasahara K., Kaneko H., Yamashina M., Kato Y., Orii T. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol. 1991 May;11(3):152–158. doi: 10.1007/BF00918683. [DOI] [PubMed] [Google Scholar]
  25. Kurlander R. J. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest. 1980 Oct;66(4):773–781. doi: 10.1172/JCI109915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lang B. A., Laxer R. M., Murphy G., Silverman E. D., Roifman C. M. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med. 1991 Aug;91(2):169–172. doi: 10.1016/0002-9343(91)90010-u. [DOI] [PubMed] [Google Scholar]
  27. Leung D. Y., Burns J. C., Newburger J. W., Geha R. S. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest. 1987 Feb;79(2):468–472. doi: 10.1172/JCI112835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lundkvist I., van Doorn P. A., Vermeulen M., Brand A. Spontaneous recovery from the Guillain-Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol. 1993 Jun;67(3 Pt 1):192–198. doi: 10.1006/clin.1993.1064. [DOI] [PubMed] [Google Scholar]
  29. Lundkvist I., van Doorn P. A., Vermeulen M., van Lint M., van Rood J. J., Brand A. Regulation of autoantibodies in inflammatory demyelinating polyneuropathy: spontaneous and therapeutic. Immunol Rev. 1989 Aug;110:105–117. doi: 10.1111/j.1600-065x.1989.tb00029.x. [DOI] [PubMed] [Google Scholar]
  30. Macey M. G., Newland A. C. CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Haematol. 1990 Dec;76(4):513–520. doi: 10.1111/j.1365-2141.1990.tb07909.x. [DOI] [PubMed] [Google Scholar]
  31. Nobile-Orazio E., Meucci N., Barbieri S., Carpo M., Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology. 1993 Mar;43(3 Pt 1):537–544. doi: 10.1212/wnl.43.3_part_1.537. [DOI] [PubMed] [Google Scholar]
  32. Overweg J., Engelfriet C. P. Cytotoxic leucocyte iso-antibodies formed during the first pregnancy. Vox Sang. 1969 Feb;16(2):97–104. doi: 10.1111/j.1423-0410.1969.tb04722.x. [DOI] [PubMed] [Google Scholar]
  33. Ravetch J. V., Kinet J. P. Fc receptors. Annu Rev Immunol. 1991;9:457–492. doi: 10.1146/annurev.iy.09.040191.002325. [DOI] [PubMed] [Google Scholar]
  34. Rossi F., Kazatchkine M. D. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol. 1989 Dec 15;143(12):4104–4109. [PubMed] [Google Scholar]
  35. Saleh M., Court W., Huster W., Shaw D., LoBuglio A. Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets. Br J Haematol. 1988 Jan;68(1):47–51. doi: 10.1111/j.1365-2141.1988.tb04178.x. [DOI] [PubMed] [Google Scholar]
  36. Schifferli J. A., Didierjean L., Saurat J. H. Immunomodulatory effects of intravenous immunoglobulin G. J Rheumatol. 1991 Jun;18(6):937–939. [PubMed] [Google Scholar]
  37. Schuller E., Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol. 1983;22(3):205–212. doi: 10.1159/000115560. [DOI] [PubMed] [Google Scholar]
  38. Shimozato T., Iwata M., Kawada H., Tamura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production. Immunology. 1991 Apr;72(4):497–501. [PMC free article] [PubMed] [Google Scholar]
  39. Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol. 1986 Jun 15;136(12):4407–4413. [PubMed] [Google Scholar]
  40. Sultan Y., Rossi F., Kazatchkine M. D. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A. 1987 Feb;84(3):828–831. doi: 10.1073/pnas.84.3.828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Tsubakio T., Kurata Y., Katagiri S., Kanakura Y., Tamaki T., Kuyama J., Kanayama Y., Yonezawa T., Tarui S. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol. 1983 Sep;53(3):697–702. [PMC free article] [PubMed] [Google Scholar]
  42. Vassilev T., Gelin C., Kaveri S. V., Zilber M. T., Boumsell L., Kazatchkine M. D. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol. 1993 Jun;92(3):369–372. doi: 10.1111/j.1365-2249.1993.tb03407.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Vermeulen M., van Doorn P. A., Brand A., Strengers P. F., Jennekens F. G., Busch H. F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):36–39. doi: 10.1136/jnnp.56.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Vermeulen M., van der Meché F. G., Speelman J. D., Weber A., Busch H. F. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci. 1985 Oct;70(3):317–326. doi: 10.1016/0022-510x(85)90173-x. [DOI] [PubMed] [Google Scholar]
  45. van Doorn P. A., Brand A., Strengers P. F., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990 Feb;40(2):209–212. doi: 10.1212/wnl.40.2.209. [DOI] [PubMed] [Google Scholar]
  46. van Doorn P. A., Vermeulen M., Brand A., Mulder P. G., Busch H. F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol. 1991 Feb;48(2):217–220. doi: 10.1001/archneur.1991.00530140113024. [DOI] [PubMed] [Google Scholar]
  47. van der Meché F. G., Schmitz P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992 Apr 23;326(17):1123–1129. doi: 10.1056/NEJM199204233261705. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES